Keros Therapeutics Inc (KROS)


Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Keros Therapeutics Inc chart...

About the Company

keros therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. the company's lead protein therapeutic product candidate is ker-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or mds, and in patients with myelofibrosis. it is also developing small molecule product candidate ker-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or fop, and is currently in a phase 1 clinical trial; and ker-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or pah. the company was founded i

Exchange

NASDAQ

Website

kerostx.com

$55M

Total Revenue

104

Employees

$2B

Market Capitalization

-12.70

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $KROS News

KROS Keros Therapeutics, Inc.

1d ago, source: Seeking Alpha

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the ...

Keros Therapeutics, Inc. (KROS) is on the Move, Here's Why the Trend Could be Sustainable

28d ago, source: Hosted on MSN

Keros Therapeutics, Inc. (KROS) is one of the several suitable candidates that passed through the screen. Here are the key reasons why it could be a profitable bet for "trend" investors.

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

28d ago, source: Business Insider

LEXINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Argenx Se (ARGX), Iridex (IRIX) and Keros Therapeutics (KROS)

1d ago, source: Business Insider

CFA covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Apogee Therapeutics, Inc., and Dianthus Therapeutics ... from Truist Financial assigned a Buy rating to Keros ...

Keros Therapeutics Inc (KROS) Reports Increased R&D Spending and Net Loss in 2023

29d ago, source: Yahoo Finance

Warning! GuruFocus has detected 3 Warning Signs with KROS. On February 28, 2024, Keros Therapeutics Inc (NASDAQ:KROS) released its 8-K filing, detailing the company's financial results for the ...

Keros Therapeutics Inc KROS

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Keros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

28d ago, source: Finanznachrichten

Keros Therapeutics Inc reports results for the quarter ended in December - Earnings Summary 28.02. Keros Therapeutics GAAP EPS of -$1.34 beats by $0.04, revenue of $0.14M ...

Keros Therapeutics Inc (KROS) Reports Increased R&D Spending and Net Loss in 2023

29d ago, source: Yahoo Finance

Warning! GuruFocus has detected 3 Warning Signs with KROS. On February 28, 2024, Keros Therapeutics Inc (NASDAQ:KROS) released its 8-K filing, detailing the company's financial results for the fourth ...

Keros Therapeutics Inc KROS

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...